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Cholesterol ester storage disease
Background: Cholesterol ester storage disease (CESD) and Wolman Disease (WD) are due to deﬁciency of
lysosomal acid lipase (LAL). A new method is described for the measurement of LAL in dried blood spots
(DBS) using Lalistat 2 an inhibitor of LAL.
Methods: LAL activity in DBS extracts was measured using the substrate 4-methylumbelliferyl palmitate. LAL
activity was determined by measuring total lipase activity and lipase activity in the presence of Lalistat 2. The
speciﬁcity of Lalistat 2 was investigated using human recombinant LAL (hrLAL) and human pancreatic lipase
(hPL).
Results: Lalistat 2 inhibited hrLAL with 1% residual activity at 1 μM inhibitor but had no effect on hPL up to
10 μM. LAL activity in DBS samples obtained from normal controls (n=140) was 0.50–2.30 nmol/punch/h
and in patients with CESD was b0.03 nmol/punch/h (n=11). Activity in carriers showed intermediate
activity: 0.15–0.40 nmol/punch/h (n=15).
Conclusions:Measurement of LAL using DBS is made difﬁcult by the presence of other lipases in whole blood.
Lalistat 2 is a speciﬁc inhibitor of LAL which allows the determination of LAL in DBS. Results show the method
differentiates clearly between normal controls, carriers and affected cases.© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Wolman disease (WD) and Cholesterol ester storage disease (CESD)
are lysosomal storage disorders due to deﬁciency of the enzyme
lysosomal acid lipase (LAL; EC 3.1.1.13). The enzyme cleaves both
cholesterol esters and triglycerides under acidic conditions. WD is the
severe form of the disorder presenting in infancy with hepatospleno-
megaly, adrenal calciﬁcation and failure to thrive. CESD is most com-
monly identiﬁed in childhood or adolescence with hepatomegaly,
premature cardiovascular disease and non alcoholic steatohepatitis
(NASH) [1]. The incidence of CESD is estimated from genetic studies
to be 1:40,000 [2], though clinically far fewer cases than this are identi-
ﬁed. The incidence of WD is estimated at approximately 1:500,000 [3].
There is no speciﬁc treatment for WD with death normally occurring
by 3 to 6 months. Current therapy for CESD consists of a low-fat diet
and lipid-lowering drugs such as statins and colestyramine [4]. There
is interest in the potential use of recombinant human LAL for enzyme
replacement therapy (ERT) in LAL deﬁcient patients [5] and the efﬁcacy
of recombinant human LAL has been demonstrated in an LAL-null
mouse model [6].
Amethod has been adapted for themeasurement of LAL inDBS based
on the method of Guy et al. [7] applied originally to the measurementamilton).
-NC-ND license.of LAL in ﬁbroblasts. LAL is measured using the ﬂuorimetric substrate
4-methylumbelliferyl palmitate (4 mU palmitate) with cardiolipin
present as an activator of LAL. The presence of other forms of lipase
in whole blood [8] will interfere with the measurement of LAL. Lalistat
2 is a speciﬁc inhibitor of LAL [9,10] and bymeasuring total lipase activ-
ity and lipase activity in the presence of Lalistat 2 LAL can be determined
in DBS.
Lalistat 1 is an analogue of Lalistat 2. They are thiadiazole carba-
mates with similar inhibitory effect on LAL [10]. Both compounds
were assessed in our assay and Lalistat 2 found to give marginally
higher activity for LAL at the same concentration of inhibitor. There-
fore Lalistat 2 was selected as the inhibitor of choice in the assay.2. Materials and methods
2.1. Samples
A reference range was established using anonymised ethylenedi-
aminetetraacetic acid (EDTA) blood obtained from samples submitted
to our laboratory for routine diagnostic testing. Blood was spotted on
to ﬁlter paper (Whatman grade 903 Schleicher & Schuell) on the day
of venepuncture and allowed to dry overnight at room temperature.
Samples were stored double-bagged with dessicant at −20 °C and
analysed within 1 week of storage. DBS samples from 11 patients
with CESD and 15 carriers were provided by Synageva BioPharma
Fig. 1. Inhibitory effect of Lalistat 2 on rhLAL. Final concentration of rhLAL 0.002 U/L.
Enzyme pre-incubated with inhibitor for 10 min. Incubation time 10 min.
Fig. 2. Inhibitory effect of Lalistat 2 on human pancreatic lipase. Final concentration
6 U/ml. Enzyme pre-incubated with inhibitor for 10 min. Incubation time 2 h.
Fig. 3. Activity derived for LAL with Lalistat 1 and Lalistat 2 using pooled DBS extract.
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written, informed consent.
2.2. Sample collection and storage for stability study
EDTA blood obtained from 3 healthy adult controls was used to
prepare DBS samples. Samples were stored at room temperature,
4 °C and −20 °C doubled-bagged with dessicant for up to 100 days.
2.3. Chemicals and reagents
Cardiolipin (sodium salt, bovine), sodium acetate (trihydrate), 4-
methylumbelliferone (4 mU), dimethylsulfoxide (DMSO), human
serum albumin (HSA) and hPL were obtained from Sigma–Aldrich
Company Ltd. (Dorset, England). 4 mU palmitate was from Apollo
Scientiﬁc Ltd (Stockport, Cheshire, UK). Mercuric chloride was from
Merck KGaA (Darmstadt, Germany). Triton X-100 was from Koch
Light (Cambridge, Cambridgeshire, UK). Lalistat 1 and Lalistat 2 were
donated by Dr. P Helquist, Chemical Tools (South Bend, IN, USA) [10].
Recombinant human LAL was supplied by Synageva Biopharma
(Lexington, Massachusetts, USA).
A buffer solution was prepared using 0.15 M acetate buffer pH 4.0,
1.0% Triton X-100. 14 ml buffer was retained at 37 °C (water bath)
and to this was added 1.0 ml 0.5% (w/v) cardiolipin in methanol
and 400 μl 13.3 mM 4 mU palmitate in DMSO (heated to 55 °C to
dissolve) to give substrate-buffer solution. 30 μM Lalistat 2 was
prepared fresh each time by diluting 200 μM Lalistat 2 (in DMSO) with
distilled water. A 30 μM working solution of Lalistat 1 was prepared
from 200 μM stock in the same way.
2.4. Sample extraction and assay procedure
3.2 mm spots were extracted with 200 μl water by mixing for 1 h
at room temperature. The assay was performed using 96 well plates
(Optiplate 96, Perkin Elmer, Cambridge, Cambridgeshire, UK). Unin-
hibited and inhibited reactions were each performed in duplicate re-
quiring 4 wells per sample. 40 μl sample was added to each well and
10 μl 30 μM Lalistat 2 was added for inhibited reaction. 10 μl water
was added to corresponding wells for uninhibited reaction. The
plate was sealed with adhesive aluminium ﬁlm and placed on a
plate shaker for 2 min followed by pre-incubation for 10 min at
37 °C. 150 μl substrate-buffer solution (retained at 37 °C until use)
was added to all wells and the plate re-sealed. The plate was shaken
for a further 2 min and incubated at 37 °C for 3 h. Reaction was
stopped by adding 100 μl 15 mM HgCl2 to all sample wells.
A 0–2.5 nmol 4 mU standard curve was made by diluting 0.5 mM
4 mU standard with water (200 μl per well) and adding 100 μl
15 mM mercuric chloride to each well. Fluorescence was measured
using a Wallac Victor 2 1420 Multilabel Counter (Perkin Elmer,
Cambridge, Cambridgeshire, UK) (excitation 355 nm, emission 460 nm).
The instrument was programmed to read the plates twice with a 5
minute interval between readings to allow dark adaptation of 4 mU.
The second reading was used to determine results. LAL activity was
determined by subtracting activity in the inhibited reaction from
uninhibited reaction (total lipase) and calculated as nmol/punch/h.
3. Results
The effect of Lalistat 2 as an inhibitor of LAL was assessed by incu-
bating Lalistat 2 with rhLAL (0.002 U/ml). Lalistat 2 was shown to in-
hibit rhLAL with only 1% residual enzyme activity remaining at a
concentration of 1 μM inhibitor (Fig. 1). The effect of Lalistat 2 on
hPL (6 U/ml) was assessed and found to have no effect on enzyme
activity up to 10 μM inhibitor (Fig. 2).
The effect of Lalistat 1 and Lalistat 2 were compared by assessing
enzyme activity using a pooled DBS extract from the same sample.Inhibitors were present at concentrations from 0.5 to 5.0 μM (Fig. 3).
Activity derived for LAL in DBS extract was higher with Lalistat 2 than
Lalistat 1 at all concentrations of inhibitor (mean difference 7%) demon-
strating more effective inhibition of LAL with Lalistat 2 than Lalistat 1.
Optimal inhibition is achieved at a concentration 1.5 μM for both
inhibitors.
The effect of pre-incubating enzyme with inhibitor was assessed
by incubating rhLAL with Lalistat 2 for up to 15 min before adding
substrate. Lalistat 2 was present at 0.1 to 10 μM. The degree of inhibi-
tion was dependant on both the concentration of inhibitor and pre-
incubation time (Fig. 4). A pre-incubation time of 5 min was the min-
imum time required for optimal inhibition with 1.0 μM Lalistat 2.
Linearity of themethodwas assessed by incubating for up to 5 h and
was shown to be adequate up to 3 h.Within-run coefﬁcient of variation
Fig. 4. Lalistat 2 (0.1–10 μM) pre-incubated with human recombinant LAL from 0 to
15 min. Fig. 6. LAL activity in 140 normal controls, 11 LAL deﬁcient patients and 15 carriers.
Limit of detection=0.02 nmol/punch/h.
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for a control with intermediate LAL activity (n=20). Between-run CV
was 5.6% for normal control (n=21) and 11.0% for intermediate control
(n=21). The limit of detection was 0.01 nmol/punch/h and limit of
quantiﬁcation was 0.02 nmol/punch/h.
Stability of LAL in DBS stored at different temperatures was
assessed by measuring enzyme activity over 100 days in samples
from controls stored at ambient temperature (~22 °C), 4 °C and
−20 °C. Samples stored at room temperature showed a fall to 94%
original activity by day 4 (Fig. 5). Storage at 4 °C showed improved
stability with 90% activity at day 21. Storage at −20 °C was optimal
with 87% activity remaining at day 100.
LAL activity in DBS from 140 controls was 0.50–2.30 nmol/punch/h
(2.5th–97.5th centile). Activity in 11 patients with CESD was
b0.03 nmol/punch/h. Activity in 15 carriers was in the range 0.15–
0.40 nmol/punch/h (Fig. 6).
4. Discussion and conclusions
The presence of other lipases in whole blood have the potential to
interfere with the measurement of LAL in DBS [8]. Rosenbaum et al.
screened ~40,000 compounds as potential inhibitors of LAL with the
aim of using LAL as a therapeutic target for Niemann–Pick disease
type C [9,10]. From this remarkable number they identiﬁed two com-
pounds, compound 12 and 13, (3,4-disubstituted thiadiazole carba-
mates) subsequently renamed Lalistat 1 (compound 13) and Lalistat
2 (compound 12) as potent competitive inhibitors of LAL using
human ﬁbroblasts and puriﬁed human LAL. They demonstrated that
both compounds had no effect on human pancreatic lipase and bo-
vine milk lipoprotein lipase.
Conduritol-B-epoxide (CBE) is used as a speciﬁc inhibitor of β-
glucocerebrosidase (GBA; EC 3.2.1.45) for the measurement of GBAFig. 5. LAL activity in DBS stored for up to 100 days at room temperature, 4 °C and –20 °C.
Results are mean percentage residual activity from three controls.in DBS to diagnose Gaucher disease [11]. By measuring total enzyme
activity and activity in the presence of inhibitor it is possible to deter-
mine the enzyme of interest. Using the same principle our aim was to
develop a method using Lalistat 2 as a speciﬁc inhibitor of LAL to
allow the measurement of LAL in DBS.
We have demonstrated that Lalistat 2 is an effective inhibitor of
recombinant human LAL in our assay with only 1% residual enzyme
activity at a concentration of 1 μM. This was similar to the ﬁndings
of Rosenbaum et al. [10]. We have also demonstrated that Lalistat 2
has no effect on human pancreatic lipase at inhibitor concentrations
up to 10 μM, again similar to the ﬁndings of Rosenbaum et al. [10].
In our assay Lalistat 2 was shown to be a more effective inhibitor of
LAL than Lalistat 1. The concentration of Lalistat 2 required for opti-
mal inhibition was 1.5 μM with a pre-incubation period of 10 min
proving to be more effective as reported by Rosenbaum et al. [10].
Stability of lysosomal enzymes in DBS varies depending on the
enzyme concerned [12–15]. LAL shows a 6% fall in activity after
4 days at room temperature. With prompt transport of samples
from referral laboratories LAL activity in DBS should be adequate for
diagnostic purposes. Long term stability at −20 °C is good with 87%
activity remaining at 100 days. Samples should be double-bagged
with a dessicant to preserve optimal activity both in transit and
long-term storage.
The method was assessed using DBS samples from 140 controls,
11 samples from patients with CESD and 15 carriers. LAL deﬁcient
samples show signiﬁcantly reduced activity with results close to
zero activity (b3% mean normal) in all 11 samples tested. Carriers
show activity grouped neatly between normals and LAL deﬁcient
cases, with all results below the reference range (Fig. 6). Therefore
the method differentiates clearly between normal activity, carriers
and LAL deﬁcient patients.
The development of a new method for the measurement of LAL in
DBS has been made possible by use of the inhibitor Lalistat 2. The
development of this new DBS method will allow screening for CESD
and WD more readily in high risk populations with the potential for
ERT in these patients.Acknowledgements
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